A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Early COPD Outcomes in Chinese Population

Trial Identifier: D2287R00187
Sponsor: AstraZeneca
Start Date: September 2024
Primary Completion Date: October 2027
Study Completion Date: October 2027
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China
China Changsha, China
China Chengdu, China
China Guangzhou, China
China Hefei, China
China Nanjing, China
China Nanning, China
China Shanghai, China
China Shenyang, China
China Wuhan, China
China Xuzhou, China
China Zhengzhou, China